Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRIM3
- Development stage
- Preclinical
- Lead developer
- StemRIM
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
TRIM3 is a synthetic regeneration-inducing peptide developed by StemRIM. It is designed for systemic administration to promote tissue repair by mobilizing the patient's own mesenchymal stem cells (MSCs) from the bone marrow into the peripheral blood. Once in circulation, these stem cells accumulate at sites of tissue damage to facilitate regeneration. TRIM3 is currently in the preclinical stage of development and is intended for a wide range of diseases involving tissue damage across multiple organs and systems. Unlike StemRIM's lead candidate Redasemtide (TRIM2), which targets HMGB1, the specific molecular target of TRIM3 has not been publicly disclosed.
- Other names
- StemRIM-novel Regeneration-Inducing peptide
Beyond the preview
Go deeper on TRIM3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIM3.